Skip to main content

Table 3 Concomitant medication at baseline in CVOTs referred to in the text

From: Current perspectives on cardiovascular outcome trials in diabetes

Concomitant medication @baseline

Antihyperglycemic medication

N (%)

CV treatment

N (%)

Insulin

Metformin

Sulphonylurea

Aspirin

Statins

Antiplatelet/anticoagulant

Beta-blocker

ACEI/ARB

Other anti-hypertensives

SAVOR-TIMI53

6757 (40.9)

11,094 (67.4)

6332 (38.5)

12,390 (75.2)

12,892 (78.3)

13,386 (81.3)

10,117 (61.4)

12,935 (78.5)

6730 (40.9)

EXAMINE

1605 (29.8)

3562 (66.2)

2503 (69.9)

4881 (90.7)

4866 (90.4)

5232 (97.2)

4411 (81.9)

4411 (81.9)

1197 (22.2)

TECOS

3408 (23.2)

11,966 (81.6)

6645 (45.3)

11,518 (78.5)

11,719 (79.9)

3167 (21.7)

9322 (63.5)

11,555 (78.8)

4961 (33.8)

ELIXA

2292 (37.8)

3834 (63.2)

1863 (30.7)

5726 (94.4)

5621 (92.6)

480 (7.9)

5119 (84.4)

5151 (84.9)

1327 (21.9)

EMPA-REG OUTCOME

2394 (34)a

3933 (55.9)a

1383 (19.6)

5990 (85)

5387 (77)

–

4537 (64)

5651 (80)

2114 (30)

LEADER

3905 (41.8)a

7136 (76.4)

4721 (50)

6523 (69.8)

6729 (72)

6322 (67.7)

5173 (55.4)

4761 (51)

920 (9.85)

SUSTAIN-6

1913 (58.0)

2414 (73.2)

1410 (42.8)

2108 (63.9)

2399 (72.8)

406 (12.3)

1894 (57.4)

1642 (49.8)

258 (7.8)

CAROLINA

–

4982 (82.5)

1728 (28.6)

3026 (50.1)

3872 (64.1)

–

2344 (38.8)

2664 (44.1)

1770 (29.3)

CANVAS

2171 (50.1)

3158 (72.9)

2032 (46.9)

 

3119 (72.0)

3073 (71.0)

   
  1. aBoth mono and dual therapy